Table 1 Baseline characteristics (n = 94)
From: Serum CGRP in migraine patients using erenumab as preventive treatment
Characteristic | |
|---|---|
Women, n (%) | 79 (84) |
Age, mean ± SD (years) | 42 ± 12.6 |
Migraine without aura, n (%) | 60 (64) |
Episodic migraine, n (%) | 52 (55) |
MMD baseline, mean ± SD | 13.7 ± 5.7 |
MHD baseline, mean ± SD | 16.5 ± 6.1 |
Failed prophylactics, mean ± SD | 5.0 ± 1.0 |